Table 1 First-Generation Drugs Second Generation Non-nitrogen containing BPs (NNBP) (Aminobisphosphonate Drugs) Nitrogen containing BPs (NBP) Bonefos
(clodronate) Actonel (risedronate sodium) Relative potency of 10 PO and IV Relative potency of 5000 PO formulations Aredia (pamidronate disodium) Didronel (etidronate disodium) Relative potency 100 IV Relative potency of 1 PO Boniva (ibandronate sodium) Skelid (tiludronic disodium) Relative potency 10000 Relative potency of 10 PO PO and IV formulations Fosamax (alendronate sodium) Relative potency 1000 PO Reclast (zoledronic acid) Relative potency 100000 IV Formulation Infused annually for osteoporosis FDA approval pendin Zometa (zoledronic acid) Relative potency 100000 IV Table 2 Risk factors Literature Of Review 1.
, Schering, Sao Paulo, Brazil) was entrapped in liposomes by ether injection as described as follows.
"Bisphosphonate Medication (Fosamax, Actonel, Boniva, Aredia, Bonefos
, Didronel or Zometa) (see Osteonecrosis of the Jaw)." The American Dental Association.
(14,15) Strikingly, short-term therapy of 3 to 10 days of IV alendronate (Fosamax) or clodronate (Bonefos
) without adverse effects resulted in significant overall improvements for the duration of the 2 trials, 4 weeks (14) and 180 days.
review: FDA's Oncologic Drugs Advisory Committee will discuss Berlex' NDA (21-776) for Bonefos
(clodronate) as an adjuvant treatment for the reduction of occurrence of bone metastases in Stage II/III breast cancer patients on Dec.
The clodronate (Bonefos
, Leiras Oy) group started with intravenous administration, 300 mg/day for 3 days, followed by oral administration of clodronate, 3200 mg/day (1600 mg twice a day) during 4 weeks.